糖尿病伤口愈合中的新型人工智能驱动精确策略:免疫调节和智能复合纳米载体的进步
Yibin Zheng1, Junshan Lan1, Qian Huang1
1School of Pharmacy and Bioengineering, Chongqing University of Technology, Chongqing 400054, China.
Pharmaceutics
|February 27, 2026
概括
智能纳米载体调节糖尿病慢性伤口 (CWs) 的免疫微环境. 人工智能 (AI) 通过优化纳米载体设计和治疗策略来实现个性化,精确的疗法,以改善治愈结果.
科学领域:
- 生物医学工程 生物医学工程
- 纳米技术纳米技术
- 免疫学 免疫学 免疫学
背景情况:
- 糖尿病慢性伤口 (CWs) 是复杂的,免疫不平衡的疾病,抵抗常规治疗.
- 目前的疗法经常失败,原因是它们的单一目标方法和无法适应伤口微环境.
研究的目的:
- 审查糖尿病CWs的免疫病理学.
- 要总结免疫调节智能复合纳米载体的发展.
- 讨论在糖尿病伤口愈合中使用人工智能支持的精密治疗框架.
主要方法:
- 对CW免疫病理学和纳米载体设计的文献进行系统审查.
- 对响应ROS,pH和酶活性的智能纳米载体功能进行分析.
- 探索人工智能集成用于风险预测,治疗优化和动态战略调整.
主要成果:
- 智能纳米载体提供了多目标,时空控制的协同干预.
- 人工智能提高了糖尿病伤口治疗计划和纳米载体设计的精度和个性化.
- 建议在CW中使用人工智能启用精密疗法的跨学科框架.
结论:
- 智能复合纳米载体代表了在CW中免疫调节的新药战略.
- 人工智能集成有助于转向针对复杂疾病的面向系统调节的纳米药学.
- 这种方法加速了先进的糖尿病伤口治疗的临床转化.
相关概念视频
Site-Targeted Drug Delivery Systems: Polymeric Carriers
59
Polymeric carriers enhance targeted drug delivery by increasing efficacy while minimizing off-target effects. These carriers comprise a biodegradable polymeric backbone integrated with functional elements that enable targeting, improve physicochemical properties, and regulate drug release.Targeting MechanismsThe targeting ability of polymeric carriers is mediated by a homing device, which is a molecular recognition component designed to selectively bind to specific tissues or cells. Monoclonal...
59
Modified-Release Drug Delivery Systems: Site-Targeted
51
Site-targeted drug delivery systems enhance therapeutic efficacy while minimizing systemic toxicity and treatment costs. Unlike conventional methods, these systems ensure precise drug delivery, improving bioavailability and reducing side effects. Targeted drug delivery is classified into three levels. First-order targeting directs drugs to the capillary beds of specific organs or tissues. Second-order targets specific cell types, such as tumor cells, using receptor-mediated interactions.
51
Clinical Applications of Epidermal Stem Cells
3.4K
Epidermal stem cells (EpiSCs) are mainly located at the basal layer of the epidermis. These cells repair minor injuries of the skin and replace dead skin cells. However, EpiSCs’ cannot heal severe wounds such as major burns or those from diabetes or hereditary disorders. In such cases, culturing the epidermal stem cells from the patient is possible and has yielded successful treatment options, such as laboratory-grown skin grafts. These grafts are synthesized using a patient’s own...
3.4K


